These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 2875864)

  • 41. Review of peptic ulcer maintenance trials.
    Robinson M
    Am J Med; 1984 Nov; 77(5B):23-9. PubMed ID: 6095657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.
    Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
    Digestion; 1985; 32 Suppl 1():32-7. PubMed ID: 2866134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multicenter, randomized, double-blind study comparing famotidine with cimetidine in the treatment of active duodenal ulcer disease.
    Rodrigo L; Viver J; Conchillo F; Barrio E; Forné M; Zozaya JM; Alvarez A; Dieguez P; Muñoz M; Panés J
    Digestion; 1989; 42(2):86-92. PubMed ID: 2570005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Famotidine in the USA: a review of efficacy studies.
    Gitnick G
    J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
    Scarpignato C; Tramacere R; Zappia L
    Br J Pharmacol; 1987 Sep; 92(1):153-9. PubMed ID: 2889492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. H2-receptor antagonists in perspective.
    Malagelada JR; Cortot A
    Mayo Clin Proc; 1978 Mar; 53(3):184-90. PubMed ID: 24155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 48. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
    Baglioni A; Barbara L; Bianchi-Porro G; Blasi A; Canelli B; Cheli R; Dal Monte R; Dammann HG; Francavilla A; Hentschel E
    Z Gastroenterol; 1985 Dec; 23(12):665-9. PubMed ID: 2868581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
    Chen PH; Wang TH; Wang CY; Chen CY; Cheng TC; Tsai YT; Siauw CP; Yang KC; Chen GH; Sung JL
    J Int Med Res; 1989; 17 Suppl 1():25A-31A. PubMed ID: 2566541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Inhibition of 24-hour acidity by nizatidine].
    Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
    Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
    Murdoch D; McTavish D
    Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical characteristics of roxatidine acetate: a review.
    Dammann HG; de Looze SM; Bender W; Labs R
    Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
    Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
    Z Gastroenterol; 1985 Feb; 23(2):47-51. PubMed ID: 2865859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cimetidine. Clinical pharmacology and toxicity (author's transl)].
    Delchier JC; Soule JC; Bader JP
    Nouv Presse Med; 1978 May; 7(20):1735-9. PubMed ID: 353705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histamine H2-receptor antagonists and gastric acid secretion.
    Pounder RE
    Pharmacol Ther; 1984; 26(2):221-34. PubMed ID: 6152495
    [No Abstract]   [Full Text] [Related]  

  • 56. MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect.
    McCallum RW; Chremos AN; Kuljian B; Tupy-Visich MA; Huber PB
    Dig Dis Sci; 1985 Dec; 30(12):1139-44. PubMed ID: 2866073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
    Bianchi Porro G; Dicenta C; Cook T; Humphries TJ
    J Clin Gastroenterol; 1987; 9 Suppl 2():14-8. PubMed ID: 2887613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Peptic ulcer: new aspects of conservative therapy].
    Bernoulli R
    Schweiz Med Wochenschr; 1977 May; 107(18):618-22. PubMed ID: 17157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
    De Natale G; De Natale F; Marino A
    Clin Ter; 1989 Apr; 129(1):3-16. PubMed ID: 2567647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.